<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
<channel>
<title>Bioline Rx Ltd — News on 6ix</title>
<link>https://6ix.com/company/bioline-rx-ltd</link>
<description>Latest news and press releases for Bioline Rx Ltd on 6ix.</description>
<language>en-us</language>
<lastBuildDate>Tue, 28 Apr 2026 11:00:00 GMT</lastBuildDate>
<generator>6ix RSS</generator>
<atom:link href="https://6ix.com/rss/company/bioline-rx-ltd" rel="self" type="application/rss+xml" />
<image>
<url>https://6ix-events-pro.s3.amazonaws.com/6ixvideo/logos/org-logo683626e878dffbe2df143cdf.webp</url>
<title>Bioline Rx Ltd</title>
<link>https://6ix.com/company/bioline-rx-ltd</link>
</image>
<item>
<title>BioLineRx and Hemispherian Announce First Patient Dosed in Phase 1/2a Study of GLIX1 for the Treatment of Glioblastoma (GBM)</title>
<link>https://6ix.com/company/bioline-rx-ltd/news/biolinerx-and-hemispherian-announce-first-patient-dosed-in-phase-12a-study-of-glix1-for-the-treatment-of-glioblastoma-gbm</link>
<guid isPermaLink="true">https://6ix.com/company/bioline-rx-ltd/news/biolinerx-and-hemispherian-announce-first-patient-dosed-in-phase-12a-study-of-glix1-for-the-treatment-of-glioblastoma-gbm</guid>
<pubDate>Tue, 28 Apr 2026 11:00:00 GMT</pubDate>
<description>BioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX), a clinical development stage biopharmaceutical company pursuing life-changing therapies in oncology and rare diseases, and Hemispherian AS, a clinical-stage oncology company developing novel small molecule therapeutics, today announced that the first patient has been dosed in the first-in-human, Phase 1/2a study of GLIX1 for the treatment of recurrent and progressive glioblastoma (GBM) and other high-grade gliomas. The GLIX1 program is being conducted</description>
</item>
<item>
<title>BioLineRx Announces Initiation of Phase 1/2a Study of GLIX1 for the Treatment of Glioblastoma (GBM)</title>
<link>https://6ix.com/company/bioline-rx-ltd/news/biolinerx-announces-initiation-of-phase-12a-study-of-glix1-for-the-treatment-of-glioblastoma-gbm</link>
<guid isPermaLink="true">https://6ix.com/company/bioline-rx-ltd/news/biolinerx-announces-initiation-of-phase-12a-study-of-glix1-for-the-treatment-of-glioblastoma-gbm</guid>
<pubDate>Thu, 26 Mar 2026 11:00:00 GMT</pubDate>
<description>BioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX), a clinical development stage biopharmaceutical company pursuing life-changing therapies in oncology and rare diseases, today announced the initiation of a first-in-human, Phase 1/2a study of GLIX1 for the treatment of recurrent and progressive GBM and other high-grade glioma (NCT07464925).</description>
</item>
<item>
<title>BioLineRx Reports 2025 Financial Results and Provides Corporate Update</title>
<link>https://6ix.com/company/bioline-rx-ltd/news/biolinerx-reports-2025-financial-results-and-provides-corporate-update</link>
<guid isPermaLink="true">https://6ix.com/company/bioline-rx-ltd/news/biolinerx-reports-2025-financial-results-and-provides-corporate-update</guid>
<pubDate>Mon, 23 Mar 2026 11:00:00 GMT</pubDate>
<description>BioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX), a development stage biopharmaceutical company pursuing life-changing therapies in oncology and rare diseases, today reported its audited financial results for the year ended December 31, 2025, and provided a corporate update.</description>
</item>
<item>
<title>BioLineRx to Report 2025 Annual Results on March 23, 2026</title>
<link>https://6ix.com/company/bioline-rx-ltd/news/biolinerx-to-report-2025-annual-results-on-march-23-2026</link>
<guid isPermaLink="true">https://6ix.com/company/bioline-rx-ltd/news/biolinerx-to-report-2025-annual-results-on-march-23-2026</guid>
<pubDate>Mon, 16 Mar 2026 11:00:00 GMT</pubDate>
<description>BioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX), a clinical development stage biopharmaceutical company pursuing life-changing therapies in oncology and rare diseases, today announced that it will release its audited financial results for the year ended December 31, 2025 on Monday, March 23, 2026, before the U.S. markets open.</description>
</item>
<item>
<title>BioLineRx Reports Third Quarter 2025 Financial Results and Provides Corporate Update</title>
<link>https://6ix.com/company/bioline-rx-ltd/news/biolinerx-reports-third-quarter-2025-120000966</link>
<guid isPermaLink="true">https://6ix.com/company/bioline-rx-ltd/news/biolinerx-reports-third-quarter-2025-120000966</guid>
<pubDate>Mon, 24 Nov 2025 12:00:00 GMT</pubDate>
<description>BioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX), a development stage biopharmaceutical company pursuing life-changing therapies in oncology and rare diseases, today reported its unaudited financial results for the quarter ended September 30, 2025, and provided a corporate update.</description>
</item>
<item>
<title>BioLineRx to Report Third Quarter 2025 Results on November 24, 2025</title>
<link>https://6ix.com/company/bioline-rx-ltd/news/biolinerx-report-third-quarter-2025-120000449</link>
<guid isPermaLink="true">https://6ix.com/company/bioline-rx-ltd/news/biolinerx-report-third-quarter-2025-120000449</guid>
<pubDate>Tue, 18 Nov 2025 12:00:00 GMT</pubDate>
<description>BioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX), a development stage biopharmaceutical company pursuing life-changing therapies in oncology and rare diseases, today announced that it will release its unaudited financial results for the third quarter ended September 30, 2025 on Monday, November 24, 2025, before the U.S. markets open.</description>
</item>
<item>
<title>BioLineRx Announces Receipt of USPTO Notice of Allowance for Key Patent Covering GLIX1 for Treating a Broad Range of Cancer Types</title>
<link>https://6ix.com/company/bioline-rx-ltd/news/biolinerx-announces-receipt-uspto-notice-120000126</link>
<guid isPermaLink="true">https://6ix.com/company/bioline-rx-ltd/news/biolinerx-announces-receipt-uspto-notice-120000126</guid>
<pubDate>Mon, 17 Nov 2025 12:00:00 GMT</pubDate>
<description>BioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX), a clinical development stage biopharmaceutical company pursuing life-changing therapies in oncology and rare diseases, today announced that the U.S. Patent and Trademark Office (USPTO) has issued a Notice of Allowance for a key patent, entitled, 'Deoxy-Cytidine or Uridine Derivatives for Use in Cancer Therapies' (Pat. Appl. Ser. No. 18/602,969), which covers the use of GLIX1 for treating cancer types in which cytidine deaminase (CDA) is not over-expres</description>
</item>
<item>
<title>BioLineRx Ltd. and Hemispherian AS Establish Joint Venture to Develop GLIX1, a First-in-Class, Oral, Small Molecule Targeting DNA Damage Response in Glioblastoma and Other Cancers</title>
<link>https://6ix.com/company/bioline-rx-ltd/news/biolinerx-ltd-hemispherian-establish-joint-110000288</link>
<guid isPermaLink="true">https://6ix.com/company/bioline-rx-ltd/news/biolinerx-ltd-hemispherian-establish-joint-110000288</guid>
<pubDate>Mon, 29 Sep 2025 11:00:00 GMT</pubDate>
<description>BioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX), a clinical development stage biopharmaceutical company pursuing life-changing therapies in oncology and rare diseases, and Hemispherian AS, a Norwegian biotech company focused on small molecule cancer therapeutics, today announced the establishment of a joint venture (JV) to develop GLIX1, a first-in-class, oral, small molecule targeting DNA damage response in glioblastoma (GBM) and other cancers. GLIX1 agonizes TET2 activity in cancer cells, resulting</description>
</item>
<item>
<title>BioLineRx Reports Second Quarter 2025 Financial Results and Provides Corporate Update</title>
<link>https://6ix.com/company/bioline-rx-ltd/news/biolinerx-reports-second-quarter-2025-110000493</link>
<guid isPermaLink="true">https://6ix.com/company/bioline-rx-ltd/news/biolinerx-reports-second-quarter-2025-110000493</guid>
<pubDate>Thu, 14 Aug 2025 11:00:00 GMT</pubDate>
<description>BioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX), a development stage biopharmaceutical company pursuing life-changing therapies in oncology and rare diseases, today reported its unaudited financial results for the quarter ended June 30, 2025, and provided a corporate update.</description>
</item>
<item>
<title>BioLineRx to Report Second Quarter 2025 Results on August 14, 2025</title>
<link>https://6ix.com/company/bioline-rx-ltd/news/biolinerx-report-second-quarter-2025-110000207</link>
<guid isPermaLink="true">https://6ix.com/company/bioline-rx-ltd/news/biolinerx-report-second-quarter-2025-110000207</guid>
<pubDate>Thu, 07 Aug 2025 11:00:00 GMT</pubDate>
<description>BioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX), a development stage biopharmaceutical company pursuing life-changing therapies in oncology and rare diseases, today announced that it will release its unaudited financial results for the second quarter ended June 30, 2025 on Thursday, August 14, 2025, before the U.S. markets open.</description>
</item>
<item>
<title>BioLineRx Announces New Pilot Phase Data from Phase 2 Combination Trial of Motixafortide in First-Line Pancreatic Cancer (PDAC) to be Presented at ASCO 2025 Annual Meeting</title>
<link>https://6ix.com/company/bioline-rx-ltd/news/biolinerx-announces-pilot-phase-data-110000297</link>
<guid isPermaLink="true">https://6ix.com/company/bioline-rx-ltd/news/biolinerx-announces-pilot-phase-data-110000297</guid>
<pubDate>Fri, 30 May 2025 11:00:00 GMT</pubDate>
<description>BioLineRx Ltd. (NASDAQ/TASE: BLRX), a development stage biopharmaceutical company pursuing life-changing therapies in oncology and rare disease, today announced that a poster including new data from the single-arm pilot phase of the investigator-initiated, randomized CheMo4METPANC Phase 2 combination clinical trial will be presented at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting, taking place May 30-June 3, 2025 in Chicago, Illinois.</description>
</item>
<item>
<title>BioLineRx Reports First Quarter 2025 Financial Results and Provides Corporate Update</title>
<link>https://6ix.com/company/bioline-rx-ltd/news/biolinerx-reports-first-quarter-2025-110000166</link>
<guid isPermaLink="true">https://6ix.com/company/bioline-rx-ltd/news/biolinerx-reports-first-quarter-2025-110000166</guid>
<pubDate>Tue, 27 May 2025 11:00:00 GMT</pubDate>
<description>BioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX), a development stage biopharmaceutical company pursuing life-changing therapies in oncology and rare diseases, today reported its unaudited financial results for the quarter ended March 31, 2025, and provided a corporate update.</description>
</item>
<item>
<title>BioLineRx to Report First Quarter 2025 Results on May 27, 2025</title>
<link>https://6ix.com/company/bioline-rx-ltd/news/biolinerx-report-first-quarter-2025-110000560</link>
<guid isPermaLink="true">https://6ix.com/company/bioline-rx-ltd/news/biolinerx-report-first-quarter-2025-110000560</guid>
<pubDate>Tue, 20 May 2025 11:00:00 GMT</pubDate>
<description>BioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX), a development stage biopharmaceutical company pursuing life-changing therapies in oncology and rare diseases, today announced that it will release its unaudited financial results for the quarter ended March 31, 2025 on Tuesday, May 27, 2025, before the U.S. markets open.</description>
</item>
<item>
<title>BioLineRx Reports 2024 Financial Results and Provides Corporate Update</title>
<link>https://6ix.com/company/bioline-rx-ltd/news/biolinerx-reports-2024-financial-results-110000630</link>
<guid isPermaLink="true">https://6ix.com/company/bioline-rx-ltd/news/biolinerx-reports-2024-financial-results-110000630</guid>
<pubDate>Mon, 31 Mar 2025 11:00:00 GMT</pubDate>
<description>BioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX), a development stage biopharmaceutical company pursuing life-changing therapies in oncology and rare diseases, today reported its audited financial results for the year ended December 31, 2024, and provided a corporate update.</description>
</item>
<item>
<title>BioLineRx to Report 2024 Annual Results on March 31, 2025</title>
<link>https://6ix.com/company/bioline-rx-ltd/news/biolinerx-report-2024-annual-results-110000681</link>
<guid isPermaLink="true">https://6ix.com/company/bioline-rx-ltd/news/biolinerx-report-2024-annual-results-110000681</guid>
<pubDate>Mon, 24 Mar 2025 11:00:00 GMT</pubDate>
<description>BioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX), a clinical-stage biopharmaceutical company pursuing life-changing therapies in oncology and rare diseases, today announced that it will release its audited financial results for the year ended December 31, 2024 on Monday, March 31, 2025, before the U.S. markets open.</description>
</item>
</channel>
</rss>